CRVS · Corvus Pharmaceuticals, Inc.
$14.10
-0.80 (-5.37%)
At close · Jul 20
Market Cap
$1.19B
Shares
84.09M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$15.28M
+75.5%
FY2025
Diluted EPS
-$0.53
+48%
FY2025
Operating Cash Flow
-$32.8M
-29%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $37.44M | $33.72M | $19.39M | $16.53M | $24.47M | $29.12M | $31.83M | $37.98M | $38.59M | $46.31M | $29.36M | $11.35M | — | |
| $10.49M | $9.25M | $8.16M | $6.88M | $8.1M | $9.52M | $11.93M | $10.88M | $10.64M | $10.22M | $7.62M | $2.42M | — | |
| $112K | $105K | $85K | $151K | $367K | $460K | $632K | $743K | $847K | $842K | $594K | $148K | — | |
| $47.93M | $42.97M | $27.55M | $23.41M | $32.57M | $38.63M | $43.76M | $48.85M | $49.22M | $56.52M | $36.98M | $13.77M | — | |
| — | — | — | — | — | — | — | — | — | — | $36.98M | $13.77M | — | |
| -$47.93M | -$42.97M | -$27.55M | -$23.41M | -$32.57M | -$38.63M | -$43.76M | -$48.85M | -$49.22M | -$56.52M | -$36.98M | -$13.77M | — | |
| -$2.02M | -$1.96M | -$3.2M | -$5.28M | -$10.01M | — | — | — | — | — | — | — | — | |
| -$42.15M | -$13.33M | -$59.1M | -$21.75M | -$41.31M | -$43.24M | -$6M | -$46.67M | -$46.94M | -$55.66M | -$36.38M | -$31.34M | -$161K | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$44.17M | -$15.28M | -$62.29M | -$27.03M | -$41.31M | -$43.24M | -$6M | -$46.67M | -$46.94M | -$55.66M | -$36.38M | -$31.34M | — | |
| -$44.17M | -$15.28M | -$62.29M | -$27.03M | — | — | — | — | — | — | — | — | — | |
| -$44.04M | -$14.89M | -$62.61M | -$27.43M | -$43.74M | -$41.38M | -$6.02M | -$46.61M | -$46.93M | -$55.67M | -$36.37M | -$31.38M | — | |
| USD/shares | — | -$0.19 | -$1.02 | -$0.56 | -$0.89 | -$1.03 | -$0.20 | -$1.59 | — | — | — | — | — |
| USD/shares | — | -$0.53 | -$1.02 | -$0.56 | -$0.89 | -$1.03 | -$0.20 | -$1.59 | — | — | — | — | — |
| shares | — | 78.96M | 60.99M | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 373.64K | — |
| shares | — | 79.74M | 60.99M | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 373.64K | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.20×
P/E (TTM)
—
Biotechnology median 7.03×
Key facts
CIK
1626971
CUSIP
221015100
13F (30d)
10 filings
10 filers
Visit website
Investor relations